Results 131 to 140 of about 1,141 (182)

Rezafungin Versus Caspofungin for the Treatment of Candidemia and Invasive Candidiasis: Results from the Double-blind, Randomized, Phase 3 ReSTORE Trial Including the China Extension Study. [PDF]

Open Forum Infect Dis
Thompson GR, Huang H, Feng S, Yu Y, Soriano A, Cornely OA, Kullberg BJ, Pappas PG, Kollef M, Vazquez JA, Honore PM, Cox L, Bassetti M.   +12 more
europepmc   +1 more source

Bad to the bone: <i>Candida (Candidozyma) auris</i> vertebral osteomyelitis treated with combination antifungal therapy followed by a novel long-acting echinocandin. [PDF]

ASM Case Rep
Jenkins LB, Christian RL, Karaman BA, Ghannoum MA, Dousa KM.   +4 more
europepmc   +1 more source

The Four Critical Priority Fungi According to the World Health Organization and the Hope for New Therapies: A Focus on Cell Wall Antifungal Targets. [PDF]

J Fungi (Basel)
Marena GD, Carvalho GC, Magalhães MHC, Figueiredo JM, Ramos DH, Nosanchuk JD, Taborda CP.   +6 more
europepmc   +1 more source

Use of the novel antifungal rezafungin in outpatient parenteral antibiotic therapy: early experience from a single centre [PDF]

Basarab, M, Bicanic, T, Davidson, H, Dunstan, I, Houston, A, Yau, T   +5 more
core   +1 more source

The looming threat of invasive fungal infections in heart transplant recipients: Will it be the last of us. [PDF]

JHLT Open
Lowe A, King ST, Hand J.
europepmc   +1 more source

Long-term Safety and Effectiveness of Rezafungin Treatment in Candidemia and Invasive Candidiasis: Results From an Early Access Program in Italy and Germany. [PDF]

Open Forum Infect Dis
Trapani F, Viceconte G, Morena V, Tiseo G, Mori G, Kölking B, Khatamzas E.   +6 more
europepmc   +1 more source

<i>Candida parapsilosis</i> and echinocandins: should the clinical laboratory drop anidulafungin Etest from the susceptibility testing panel? [PDF]

Antimicrob Agents Chemother
Vahedi-Shahandashti R, Moroder E, Lass-Flörl C.   +2 more
europepmc   +1 more source

Faculty Opinions recommendation of The antifungal pipeline: fosmanogepix, ibrexafungerp, olorofim, opelconazole, and rezafungin.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature, 2021
openaire   +2 more sources

Activity of Rezafungin Against Echinocandin Non-wild type <i>Candida glabrata</i> Clinical Isolates From a Global Surveillance Program. [PDF]

Open Forum Infect Dis
Castanheira M, Deshpande LM, Kimbrough JH, Winkler M.   +3 more
europepmc   +1 more source

<i>In vitro</i> activity of novel antifungals, natamycin, and terbinafine against <i>Fusarium</i>. [PDF]

Antimicrob Agents Chemother
Garbe E, Ullah A, Aldejohann AM, Kurzai O, Janevska S, Walther G.   +5 more
europepmc   +1 more source